antianginal/illamående

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 28 resultat

Trials with an adenosine analogue as antianginal medication.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The potential antianginal effects of orally administered ethyl-adenosine-5-carboxylate hydrochloride (EACH) were assessed in 9 patients with stable angina pectoris who underwent two standardized exercise tests for 3 consecutive days. The first daily exercise performed after placebo revealed no daily

Ranolazine Induced Bradycardia, Renal Failure, and Hyperkalemia: A BRASH Syndrome Variant.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Ranolazine is a well-known antianginal drug, that was first licensed for use in the United States in 2006. It was objectively shown to improve exercise capacity and to lengthen the time to symptom onset in patients with coronary artery disease. The most commonly reported side effects of ranolazine

[Feasibility and safety of dobutamine stress echocardiography: experiences with 1,000 studies].

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The use of dobutamine stress echocardiography for the evaluation of coronary artery disease is rapidly expanding. Despite its widespread use, the feasibility and safety of dobutamine stress echocardiography has not been sufficiently documented. Between November 1992 and June 1995, we performed 1000

Nicorandil-associated ulcerations.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

This leading article refers to the paper by Abdelrazeq AS, Owen C, Smith L, McAdam JG, Pearson HJ, Leveson SH. Nicorandil-associated para-stomal ulceration: case series Eur J Gastroenterol Hepatol 2006; 18:1293-1295. We apologise to all concerned for the dissociation between the two papers, which

Polypharmacy in Palliative Care: Two Deprescribing Tools Compared with a Clinical Review

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Background: Lack of guidance is highlighted as a barrier to deprescribing in palliative care. Two deprescribing tools exist, but with inclusion and exclusion criteria that limit utility. The tools have not previously been compared directly or used in an unselected palliative

Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Bepridil, a new calcium-channel blocking agent with an extended plasma elimination half-life of greater than 50 hours, was compared to placebo in 77 patients with confirmed coronary artery disease and chronic stable angina pectoris. The effects of bepridil were compared with those of placebo on

An 8-week double-blind study of amlodipine and diltiazem in patients with stable exertional angina pectoris.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A multicenter, double-blind study was performed to compare the antianginal efficacy and safety of the new dihydropyridine calcium antagonist amlodipine with the benzothiazepine calcium antagonist diltiazem in patients with stable exertional angina pectoris. Following a 2-week placebo run-in period,

Amlodipine combined with beta blockade for chronic angina: results of a multicenter, placebo-controlled, randomized double-blind study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Amlodipine, a potent long-acting dihydropyridine calcium antagonist, was compared with placebo in a parallel, randomized, double-blind study in 134 patients with chronic stable angina pectoris maintained on beta-adrenergic blocking agents. After a single-blind, two-week placebo period, patients were

Clinical experience with a transdermal nitroglycerin system.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Forty-seven patients with chronic stable angina pectoris entered a thirteen-week open-label study with a transdermal therapeutic system of nitroglycerin in order to evaluate its clinical efficacy, safety, and patient acceptance. In 19 patients, a beta-blocker and in 17 patients a calcium-channel

Treating angina pectoris by acupuncture therapy.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Acupuncture therapy on PC 6 (Neiguan) has a therapeutic effect on cardiac and chest ailments including angina pectoris. Additional beneficial acupuncture points are PC 4 (Ximen), HT 7 (Shenmen point), PC 7 (Daling point), PC 5 (Jianshi point), PC 3 (Quze point), CV 17 (Danzhong point), CV 6 (Qihai

Ranolazine: a review of its use as add-on therapy in patients with chronic stable angina pectoris.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Extended-release ranolazine (ranolazine ER) [Ranexa(®)] is an antianginal agent that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). This article reviews the efficacy, safety and

Bepridil treatment of chronic stable angina: a review of comparative studies versus placebo, nifedipine, and diltiazem.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The antianginal efficacy of bepridil, a calcium antagonist with an extended plasma elimination half-life, has been compared with placebo and the calcium antagonists nifedipine and diltiazem in patients refractory to diltiazem. The earliest observations in the United States of antianginal effects of

Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A number of newer antianginal agents, including nicorandil, trimetazidine, and ivabradine, have been synthesized in recent years, but ranolazine, a piperazine derivative that partially inhibits fatty acid oxidation and the late INa current in animal models, is of particular interest mechanistically.

Sustained effects of transdermal nitroglycerin in patients with angina pectoris.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

The antianginal efficacy of a transdermal therapeutic delivery system for nitroglycerin (TNG) was compared with that of placebo in a double-blind crossover study. Twenty-five patients with stable angina pectoris were evaluated. The transdermal system delivered 5 mg of nitroglycerin over a 24-hour

Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE The anti-anginal efficacy of the selective I(f) inhibitor ivabradine has been demonstrated in controlled clinical trials. However, there is limited information about the safety and efficacy of a combined treatment of ivabradine with beta-blockers, particularly outside of clinical trials in

Tidigare
1
2
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning